Therapeutic Solutions International
Reports Augmentation of Cancer Immunotherapy using
Pterostilbene
OCEANSIDE, CA -- July 11, 2016 -- InvestorsHub NewsWire
-- Therapeutic Solutions International, Inc., (OTC
Markets:TSOI) reported novel data supporting the
use of pterostilbene, a natural analog of resveratrol with greater
bioavailability, as an adjuvant to immunotherapy of cancer in a
murine melanoma model. The reported data, which is part of the
Companys filed Utility Patent #15/204560, demonstrated a synergy of
inhibiting melanoma growth between pterostilbene and a T cell
activating a FDA approved immunotherapeutic, as well as
augmentation of immune stimulating cytokines. Cytokines are
molecular signals the immune system uses to coordinate attacks on
pathogenic invaders as well as cancer cells.
Inventors on the patent are Thomas Ichim, Ph.D., Timothy Dixon,
Robert Graham, Gerry Berg, and Santosh Kesari, MD, Ph.D. The patent
covers various combinations of pterostilbene with
immunotherapeutics for the purpose of augmenting efficacy in both
the stimulation of immune killer cells, as well as immune cells
that reduce growth of cancer cells.
"Although immunotherapeutics of cancer is a rapidly evolving
field, these approaches induce various biochemical manipulations of
the body, which in many cases cause nutrient and oxidative
dis-balances. We believe that administration of pterostilbene
effectively restores dis-balances caused by immunotherapy, thus
resulting in enhanced efficacy", said Timothy Dixon, President and
CEO of Therapeutic Solutions International.
Pterostilbene is the star ingredient of ProJuvenol, a
nutraceutical currently sold by the Company and available online at
www.youcanordernow.com. ProJuvenol is a powerful
synergistic blend of complex anti-aging ingredients inspired by
nature to help promote cellular rejuvenation and healthy
functionality for everyday living, based in pterostilbene, one
of natures unique and intelligent
antioxidants/anti-inflammatories.
"We are thankful for our academic collaborators who have
generated this new and exciting data. We are in the process of
performing additional experiments and hope to publish these data in
the peer-reviewed literature in the near future", said Thomas
Ichim, Ph.D., Board Member of TSOI. "Examples of immunotherapeutics
that would be enhanced by pterostilbene, if the data we reported is
extrapolatable to humans, include Herceptin, Rituximab, and
Cetuximab", added Dr. Ichim.
About Therapeutic Solutions International,
Inc.
The Company's corporate website is www.therapeuticsolutionsint.com.
Our new products can be viewed on www.projuvenol.com and products
can be ordered at www.youcanordernow.com.
These Supplement products have not been evaluated by the United
States Food and Drug Administration. These products are not
intended to diagnose, treat, cure or prevent any diseases.
Safe Harbor Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. The reader is cautioned not
to put undue reliance on these forward-looking statements, as these
statements are subject to numerous risk factors as set forth in our
SEC filings. To the extent that statements in this press release
are not strictly historical, including statements as to product
launch timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements made.
CONTACT INFORMATION
Therapeutic Solutions International, Inc.
ir@tsoimail.com